A study in Clinical Gastroenterology and Hepatology found that the prevalence of metabolic dysfunction-associated steatotic liver disease is high and growing worldwide among individuals with type 2 diabetes, with the global pooled NAFLD/MASLD prevalence in patients with diabetes reaching almost 69%. “Almost 2 out of 3 patients with T2D and NAFLD/MASLD have NASH/MASH, and 15% have advanced fibrosis," the researchers wrote.
Full Story: Gastroenterology Advisor (4/25)